Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
1991 Standout
Risk Factors for Bleeding during Treatment of Acute Venous Thromboembolism
1996
Fatty acid transport: difficult or easy?
1998
Parenteral Anticoagulants
2008
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half‐life in man.
1987
Parenteral Anticoagulants
2012 Standout
Heparin-Protein Interactions
2002 Standout
Structure and Biological Activity of Heparin
1985
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
1988
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Low-molecular-weight Heparins for the Treatment of Venous Thromboembolism
1993
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
1995
Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism
2000
Does protamine chloride neutralize low molecular weight heparin sufficiently?
1988
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
1996
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo
1989
Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin
1995
Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors
1987
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
1996 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
A Kinetic Study of the Growth of Fatty Acid Vesicles
2004 StandoutNobel
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin
1996
Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study
1996
Heparin and Low-Molecular-Weight Heparin
2004
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Myocardial Substrate Metabolism in the Normal and Failing Heart
2005 Standout
Mechanisms responsible for the failure of protamine
to inactivate low‐molecular‐weight heparin
2002
Pentosan polysulfate‐induced thrombocytopenia and thrombosis
1994
The effect of molecular weight on heparin binding to platelets
1990
Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin
1992
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) - a multicenter co-operative double-blind trial in comparison with heparin -
1993
Cardiac fatty acid uptake and transport in health and disease
2000
A Comparison of Subcutaneous Low-Molecular-Weight Heparin with Warfarin Sodium for Prophylaxis against Deep-Vein Thrombosis after Hip or Knee Implantation
1993
Measuring the degree of plasma contact activation induced by artificial materials
2002
Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin
1988
Characterization of recombinant human .alpha.2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site
1987
Characterization of the heparin-binding site of glia-derived nexin/protease nexin-1
1992
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
2006
The creation of an antithrombotic surface by apyrase immobilization
2010 StandoutNobel
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
1990
Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
1996
Disseminated Intravascular Coagulation
1999 Standout
Heparin
1991
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin
1990
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
1992
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine
1995
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
Organic Azides: An Exploding Diversity of a Unique Class of Compounds
2005 Standout
Cellulose: Fascinating Biopolymer and Sustainable Raw Material
2005 Standout
Venous Thromboembolism in Spinal Cord Injury Patients
1992
Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.
1991
Outpatient treatment of deep vein thrombosis: translating clinical trials into practice
1999
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Glycosaminoglycans and the regulation of blood coagulation
1993
A 96-well dot-blot assay for carbohydrate sulfotransferases
2002 StandoutNobel
Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
1983
The antithrombin-binding sequence of heparin. Location of essential N-sulfate groups.
1981
The Binding of Low-Affinity and High-Affinity Heparin to Antithrombin. Fluorescence Studies
1978
Extracellular DNA traps promote thrombosis
2010 Standout
Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin.
1994
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Diurnal Rhythm in Anticoagulant Effect of Heparin during a Low Dose Constant Rate Infusion
1992
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin.
1980
Serpin Structure, Mechanism, and Function
2002 Standout
The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria
1995
Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies
1978
A new low molecular weight heparin derivative. In vitro and in vivo studies
1983
The effect of platelet factor 4 (PF4) on assays of plasma heparin
1984
Energetics and Dynamics of Enzymatic Reactions
2001 StandoutNobel
Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
1984
The relative contributions of antithrombin iii during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism.
1987
The heparin-enhanced antithrombin III/thrombin reaction is saturable with respect to both thrombin and antithrombin III.
1982
Myocardial Fatty Acid Metabolism in Health and Disease
2010 Standout
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence Chemical and13C nuclear-magnetic-resonance studies
1981
Sulphated Sugar Alpha-Cyclodextrin Sulphate, a Uniquely Potent Anti-HIV Agent, Also Exhibits Marked Synergism with AZT, and Lymphoproliferative Activity
1990
Membrane growth can generate a transmembrane pH gradient in fatty acid vesicles
2004 StandoutNobel
Anticoagulation Monitoring during Cardiac Surgery
1999
Kinetics of intravenously administered heparin in normal humans
1982
Comparison of Once-Daily Subcutaneous Fragmin® with Continuous Intravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis
1994
In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative
2010
Mechanism of inactivation of trypsin by antithrombin
1982
Neutralization of heparin by histone and its subfractions
1983
Shrink-Wrap Vesicles
2005 StandoutNobel
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis
1985
Cyclodextrin Drug Carrier Systems
1998 Standout
Mechanisms of adenosine triphosphate-, thrombin-, and trypsin-induced relaxation of rat thoracic aorta.
1984 StandoutNobel
Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
1984
Low molecular weight heparin
1992
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
1988
Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
1989
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Effect of Heparin and Heparin Fractions on Platelet Aggregation
1980
Further characterization of the antithrombin-binding sequence in heparin
1982 Standout
Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
1992
Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins
1993
Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4.
1986
The antithrombin-binding sequence of heparin studied by n.m.r. spectroscopy
1981
Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study
1985
Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.
1982
Partial NH2- and cooh-terminal sequence analyses of Eco RI DNA restriction and modification enzymes.
1981 StandoutNobel
Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)
1990
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
1993
A Randomized Double-Blind Study Between a Low Molecular Weight Heparin Kabi 2165 and Standard Heparin in the Prevention of Deep Vein Thrombosis in General Surgery
1988
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
1988
Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.
1980
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
1983
Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin
1994
Low Molecular Weight Heparin and Prevention of Postoperative Thrombosis in Abdominal Surgery
1992
Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo
1982
Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
1986
A survey of recent advances in selective chemical and enzymic polysaccharide modifications
1985
Heparin with two binding sites for antithrombin or platelet factor 4.
1982
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell‐induced vaso‐occlusion
2016
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Low-Molecular-Weight Heparins
1997 Standout
Die charakteristische AT‐III‐Bindungsregion in Heparin: eine Leitstruktur für neue synthetische Antithrombotica
1993
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator
1986
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
1994
Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
1983
Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin
1982
Some properties of antithrombin-III and its concentration in human plasma
1980
Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration
1985
Inhibition of low molecular weight heparin by protamine chloride in vivo
1985
Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.
1986
The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
1988
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.
1993
The molecular size of the antithrombin‐binding sequence in heparin
1980
Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis
1986
Importance of Size, Sulfation, and Anticoagulant Activity in the Potentiation of Acidic Fibroblast Growth Factor by Heparin
1989
Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery
1996
Structure of the antithrombin-binding site in heparin.
1979
Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin
1989
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
1984
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Extension and structural variability of the antithrombin-binding sequence in heparin.
1984
Catabolism of low-dose heparin in man
1979
Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits
1985
Fluorescence-Based Blood Coagulation Assay Device for Measuring Activated Partial Thromboplastin Time
2010 StandoutNobel
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: Evidence for conformational peculiarity of the sulfated iduronate residue
1985
The molecular-weight-dependence of the anti-coagulant activity of heparin
1978
The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue.
1980
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers
1986
Antithrombotic Therapy for Venous Thromboembolic Disease
1995
Low molecular weight heparin
1992
Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
1993
Works of E. Holmer being referenced
Sevuparin : effects on hemostasis of a novel polysaccharide drug derived from heparin
2015 Nobel
Antithrombotic Effects of Heparin Oligosaccharides
1989
Heparin-Coated Stents
2000
FragminTM (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits
1994
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration
1977
Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration
1976
Low-molecular-weight heparin (FragminTM) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model
1994
Studies on the blood-anticoagulant activity of sulphated polysaccharides with different uronic acid content
1982
Mechanisms of anticoagulant effects of some sulphated polysaccharides
1982
Anticoagulant activities of a pentosane polysulphate: Comparison with standard heparin and a fraction of low molecular weight heparin
1980
Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
1982
Studies on the Mechanism of the Rate‐Enhancing Effect of Heparin on the Thrombin‐Antithrombin III Reaction
1979
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin
1981
Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin
1980
The preparation of a heparin analogue frorn alginic acid
1979
Elimination of high affinity heparin fractions and their anticoagulant and lipase activity
1984
Properties of antithrombin III depleted plasma I. Effect of heparin
1980
Heparin and Its Low Molecular Weight Derivatives: Anticoagulant and Antithrombotic Properties
1986
A new method for the measurement of dissociation rates for complexes between small ligands and proteins as applied to the palmitate and bilirubin complexes with serum albumin
1974
Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
1984
ANTICOAGULANT PROPERTIES OF HEPARIN AND HEPARIN FRACTIONS
1980
Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
1979
Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously
1983